New York Valves 2026: The Late-Breaking Data Cardiologists Should Know

A high-yield digest of the trial updates, registry data, and guideline signals presented at structural heart's flagship June meeting.

More than 3,000 interventional cardiologists, surgeons, and imagers convened at the Jacob K. Javits Convention Center for New York Valves 2026, the structural heart community's flagship June meeting.

Across three days, the program delivered roughly 30 late-breaking presentations spanning aortic, mitral, and tricuspid disease, alongside a dedicated left atrial appendage closure (LAAC) summit and six FDA town halls.

For clinicians who could not attend in person, five storylines stand out for their bearing on everyday valve referral and follow-up decisions.

3,000+Attendees

30Late-breaking presentations

4+2LB clinical science / innovation sessions

1.5 daysLAAC summit

20Live-case sessions

6FDA town halls

Figure 1. New York Valves 2026 by the numbers.

Asymptomatic Severe AS: Rethinking "Watch and Wait"

The asymptomatic severe aortic stenosis (AS) debate anchored the opening session, built around an updated 5-year analysis of the EARLY TAVR trial.

Early transcatheter aortic valve replacement (TAVR) continued to outperform clinical surveillance for the composite of death, stroke, or unplanned cardiovascular hospitalization, reinforcing the trial's original findings.

A parallel session reviewed 7-year valve durability data from PARTNER 3, which showed comparable clinical outcomes and hemodynamic performance between TAVR and surgical replacement in low-risk patients.

Taken together, both data sets support a lower threshold for intervention in anatomically suitable, low-risk patients rather than indefinite serial echocardiographic surveillance.

The 2025 ESC/EACTS valvular heart disease guidelines have already moved in this direction, now endorsing intervention in asymptomatic patients with severe high-gradient AS and preserved ejection fraction when procedural risk is low.

Tricuspid Regurgitation: Durability Signals Emerge

Tricuspid disease received its own late-breaking session, headlined by 2-year outcomes from TRISCEND II.

Transcatheter tricuspid valve replacement (TTVR) sustained reduction in tricuspid regurgitation and symptom benefit through 2 years compared with medical therapy alone.

Investigators also flagged an early signal toward a mortality advantage, a finding that, if it holds up, would mark a meaningful shift for a disease long managed expectantly.

Companion talks addressed device thrombosis after TTVR and outcomes of edge-to-edge repair in patients who had already failed a first repair attempt, underscoring that tricuspid intervention is maturing past first-generation questions.

Mitral Disease: Filling the Anatomic Gaps

The single late-breaking mitral session centered on patients who fall outside standard device indications.

One-year registry data on transcatheter mitral valve replacement in mitral annular calcification suggested a feasible option for a population historically excluded from both surgery and edge-to-edge repair.

Additional presentations compared real-world outcomes between two leading mitral edge-to-edge repair systems and examined repeat repair in patients whose first procedure had failed.

Collectively, these analyses chip away at the remaining "no-option" mitral phenotypes that heart teams routinely encounter.

Pure Aortic Regurgitation: A Pacemaker Trade-off

Native aortic regurgitation (AR) remains underserved by conventional TAVR platforms, which are engineered around calcified anatomy.

A dedicated-device trial, ALIGN-AR, has shown high technical success and elimination of significant residual AR using a valve built specifically for non-calcified annuli.

The trade-off has been a new permanent pacemaker rate near one in four patients, and a late-breaking analysis at the meeting examined predictors of that pacing need.

Until a dedicated device gains broader approval, off-label TAVR in pure AR should remain a heart-team decision made with this pacing risk clearly in view.

Screening and Innovation: Finding What the Eye Misses

A late-breaking innovation session highlighted AI-enabled ECG screening that flags structural heart disease from a standard 12-lead tracing.

In one published case, the algorithm identified previously unrecognized severe AS in an asymptomatic patient who went on to TAVR, illustrating how automated screening can shorten the path from incidental finding to definitive treatment.

This kind of tool complements the Target: Aortic Stenosis initiative, a national quality program built to close the persistent gap between echocardiographic AS diagnosis and timely referral.

Closing the diagnosis-to-treatment gap, rather than developing yet another device, may be where the next incremental survival benefit in AS actually comes from.

Day 1 — Wed

TAVI durability (PARTNER 3) and tricuspid late-breakers; asymptomatic AS debate opens the Heart Team Arena; LAAC Summit begins.

Day 2 — Thu

Mitral late-breakers (MAC, repeat M-TEER); AI-ECG innovation session; postapproval TMVR landscape.

Day 3 — Fri

2025 ESC aortic guideline review; AS registries (PROGRESS, DETECT AS II); ALIGN-AR pacemaker analysis.

Figure 2. How the late-breaking science was distributed across the three meeting days.

Table 1. Late-Breaking Data Snapshot — New York Valves 2026

Trial / Registry	Valve Domain	Follow-up	Headline Finding
EARLY TAVR	Aortic — asymptomatic severe AS	5 years	Early TAVR sustained lower death/stroke/unplanned CV hospitalization vs. surveillance
PARTNER 3	Aortic — low-risk symptomatic AS	7 years	TAVR and SAVR comparable on death/stroke/rehospitalization and valve durability
TRISCEND II	Tricuspid regurgitation	2 years	Sustained TR reduction and symptom benefit; early mortality signal
ALIGN-AR	Native aortic regurgitation	30 days–1 year	Eliminated significant residual AR; ~1-in-4 new pacemaker rate
TMVR-MAC registry	Mitral annular calcification	1 year	Feasible option in anatomy excluded from surgery/edge-to-edge repair
AI-ECG screening	Cross-valvular	Case-level	Flagged unrecognized severe AS, prompting TAVR referral

Table 2. What Changed: 2025 ESC/EACTS Practice Signals

Clinical Scenario	Prior Practice Norm	2025 Guideline Direction
Asymptomatic severe high-gradient AS, low risk	Serial echo surveillance	Earlier intervention reasonable if procedural risk is low
Tricuspid (trileaflet) AS	TAVI favored ≥75 years	Age threshold lowered to ≥70 years
Atrial secondary mitral regurgitation	No dedicated recommendation	New Class IIa surgery / IIb transcatheter guidance
Pure native AR, high surgical risk	Off-label TAVR only	Dedicated-device data supportive; pacemaker risk a key counseling point
Undiagnosed structural heart disease	Symptom- or murmur-triggered echo	AI-ECG screening adds an asymptomatic detection pathway

Case in Point

A 74-year-old man with no cardiac symptoms undergoes a routine preoperative ECG before elective hip surgery, and an AI-enabled ECG algorithm flags the tracing as suggestive of structural heart disease.

Echocardiography reveals severe, high-gradient AS with preserved ejection fraction, and a negative treadmill test confirms his asymptomatic status.

Under older surveillance-only norms, he would likely have been scheduled for a repeat echocardiogram in 12 months and sent on to surgery.

Citing the 2025 ESC/EACTS guidance and the updated EARLY TAVR follow-up data, the heart team instead pursues earlier TAVR evaluation given his low procedural risk and favorable anatomy, illustrating how this year's data and screening tools can change a default decision pathway.

Bottom Line

• Updated EARLY TAVR follow-up and the 2025 ESC/EACTS guidelines both now favor earlier intervention over indefinite surveillance in low-risk, anatomically suitable asymptomatic severe AS.
• TTVR is maturing past symptom relief alone, with 2-year TRISCEND II data hinting at a mortality benefit that warrants longer follow-up.
• Pure native AR is treatable with a dedicated transcatheter device, but patients should be counseled on a roughly 1-in-4 new pacemaker rate.
• AI-enabled ECG screening is an emerging, low-cost lever for catching unrecognized structural heart disease before symptoms force the issue.

References

1. What's Going to Be Hot at New York Valves 2026 — TCTMD
2. New York Valves 2026 To Unveil Late-Breaking Research in Structural Heart Disease — Cardiovascular Research Foundation
3. New York Valves 2026 — Conference Overview
4. PARTNER 3: TAVR vs. Surgery in Low-Risk Patients at 7 Years — American College of Cardiology
5. EARLY TAVR: 5-Year Data Still Support TAVI Over Surveillance in Asymptomatic AS — TCTMD
6. Hints of a Mortality Benefit With TTVR at 2 Years: TRISCEND II — TCTMD
7. TAVR With JenaValve for Symptomatic Aortic Regurgitation in High Surgical Risk Patients — American College of Cardiology
8. 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease — European Society of Cardiology
9. Target: Aortic Stenosis — American Heart Association
10. Cardiologists Develop New AI Screening Tool for Structural Heart Disease — Cardiovascular Business

This article is intended for physician education and summarizes publicly presented and published data. It is not a substitute for individualized clinical judgment, current society guidelines, or multidisciplinary Heart Team decision-making for any specific patient.